Business Combination - Schedule of the Total of Purchase Consideration (Details) - Avadel Pharmaceuticals Plc $ in Thousands |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
USD ($)
| |
| Business Combination [Line Items] | |
| Cash consideration paid for Avadel's ordinary shares | $ 2,064,310 |
| Cash consideration paid for cash settlement of Avadel equity awards | 134,897 |
| Fair value of CVR contingent consideration | 107,713 |
| Total preliminary purchase consideration | $ 2,306,920 |
| X | ||||||||||
- Definition Cash consideration for settlement of unvested share based compensation awards. No definition available.
|
| X | ||||||||||
- Definition Cash consideration paid for ordinary shares. No definition available.
|
| X | ||||||||||
- Definition Fair value of contingent consideration. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|